Celltrion Applies for Conditional Approval of COVID-19 Treatment in South Korea
[Asia Economy Reporter Park Jun-yi] Celltrion announced on the 29th that it has applied for conditional approval in South Korea from the Ministry of Food and Drug Safety for the treatment of patients infected with the novel coronavirus disease (COVID-19), 'CT-P59.'
Hot Picks Today
Taking Annual Leave and Adding "Strike" to Profiles, "It Feels Like Samsung Has Collapsed"... Unsettled Internal Atmosphere
- There Is a Distinct Age When Physical Abilities Decline Rapidly... From What Age Do Strength and Endurance Drop?
- "One Comment Could Lead to a Report": 86% of Elementary Teachers Feel Anxious; Half Consider Resignation or Career Change
- "After Vowing to Become No. 1 Globally, Sudden Policy Brake Puts Companies’ Massive Investments at Risk"
- On Teacher's Day, a Student's Gifted Cake Had to Be Cut into 32 Pieces... Why?
Celltrion stated, "Upon obtaining conditional approval for CT-P59, we plan to supply the COVID-19 treatment immediately for therapeutic use in medical settings," and added, "We will continue efforts to demonstrate the efficacy and safety of CT-P59 through ongoing clinical trials."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
